A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

OBJECTIVES: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Smolen, Josef S, Behrens, Frank, Nash, Peter, Liu Leage, Soyi, Li, Lingnan, Tahir, Hasan, Gooderham, Melinda, Krishnan, Eswar, Liu-Seifert, Hong, Emery, Paul, Pillai, Sreekumar G, Helliwell, Philip S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937408/
https://www.ncbi.nlm.nih.gov/pubmed/31563894
http://dx.doi.org/10.1136/annrheumdis-2019-215386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937408/
https://www.ncbi.nlm.nih.gov/pubmed/31563894
http://dx.doi.org/10.1136/annrheumdis-2019-215386

Ejemplares similares